Results 271 to 280 of about 4,457,527 (301)
Some of the next articles are maybe not open access.
Blood Reviews, 2001
T hrombolytic therapy represents part of a conjoint approach to achieving vascular reperfusion, based primarily on the use of fibrinolytic agents delivered systemically or directly into the offending thrombus and complemented by anticoagulation, antiplatelet, and even mechanical strategies.
openaire +3 more sources
T hrombolytic therapy represents part of a conjoint approach to achieving vascular reperfusion, based primarily on the use of fibrinolytic agents delivered systemically or directly into the offending thrombus and complemented by anticoagulation, antiplatelet, and even mechanical strategies.
openaire +3 more sources
The American Journal of Cardiology, 1991
In the past decade, mortality associated with acute myocardial infarction has been reduced to between 5% and 9% in selected groups of patients, largely due to use of early reperfusion. Thrombolytics combined with aggressive mechanical revascularization reduce the likelihood of death both during hospitalization and in the ensuing several years.
openaire +3 more sources
In the past decade, mortality associated with acute myocardial infarction has been reduced to between 5% and 9% in selected groups of patients, largely due to use of early reperfusion. Thrombolytics combined with aggressive mechanical revascularization reduce the likelihood of death both during hospitalization and in the ensuing several years.
openaire +3 more sources
Advances in thrombolytic therapy
Cardiovascular Drugs and Therapy, 1992Alteplase and saruplase are more fibrin-specific thrombolytic drugs than anistreplase. These and the thrombolytic drugs of the first generation (streptokinase and urokinase) have shortcomings and limitations. The prolonged intravenous maintenance infusions have been replaced by a bolus injection, accelerated infusions, or the combined intravenous ...
openaire +3 more sources
Platelets and Thrombolytic Therapy
New England Journal of Medicine, 1990FIBRINOLYTIC therapy is a major advance in the treatment of occlusive vascular disease. Problems remain, however, including resistance to fibrinolytic therapy, delays in reperfusion, reocclusion after successful thrombolysis, and serious hemorrhage.1 2 3 Increasing evidence indicates that platelets have an important role in both delaying reperfusion ...
openaire +2 more sources
Fibrinolytic Enzymes for Thrombolytic Therapy.
Advances in Experimental Medicine and Biology, 2019Swaroop S. Kumar, A. Sabu
semanticscholar +1 more source